Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03386513 · ClinicalTrials.gov registry record · Phase 1
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
A Phase 1 study of Myeloproliferative Neoplasm and Blastic Plasmacytoid Dendritic Cell Neoplasm, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT03386513 is a Phase 1 study of Myeloproliferative Neoplasm and Blastic Plasmacytoid Dendritic Cell Neoplasm that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 179 participants, above the 80-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03386513, a Phase 1 study of Myeloproliferative Neoplasm and Blastic Plasmacytoid Dendritic Cell Neoplasm, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
Conditions Studied
Interventions
- DRUG IMGN632
Study Locations (20)
Other
- Recherche Clinique-Hématologie - Amiens
- CHU de Besancon, Hopital Jean Minjoz - Besançon
- Institut Paoli Calmettes (Marseille) - Marseille
- Hôpital St Antoine - Paris
- CHU Bordeaux Hôpital Haut-Lévêque - Pessac
California
- City of Hope Medical Center - Duarte
- UCLA - Los Angeles
- Stanford - Stanford
North Carolina
- Novant Health Cancer Institute Hematology - Charlotte
- Duke Cancer Institute - Durham
- Novant Health Cancer Institute Hematology - Forsyth - Winston-Salem
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Baylor Scott & White University Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Banner Health MD Anderson Cancer Center - Gilbert
Florida
- Moffitt Cancer Center - Tampa
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03386513
The ClinicalTrials.gov registry entry for NCT03386513 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 80-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (124% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which IMGN632 is the first listed.
NCT03386513 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03386513 about?
NCT03386513 is a clinical study titled "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN". This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.
What is the current status of trial NCT03386513?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2018-01-02. Estimated completion is 2026-12-30.
What conditions does trial NCT03386513 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm.
What interventions are being tested in trial NCT03386513?
The interventions under investigation include: IMGN632 (DRUG).
Who is sponsoring clinical trial NCT03386513?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03386513 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RECRUITING · Phase 1
-
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
RECRUITING · Phase 1
-
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
RECRUITING · Phase 1
-
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
RECRUITING · Phase 1
-
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
RECRUITING · Phase 1
-
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
RECRUITING · Phase 1
Explore more on PlainTrial
Myeloproliferative Neoplasm
All registered trials for this condition
Blastic Plasmacytoid Dendritic Cell Neoplasm
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.